Skip to main content
AML treatment gains fast-track status
10/12/2017

The FDA gave fast-track status to Astellas' acute myeloid leukemia treatment gilteritinib, an FLT3/AXL tyrosine kinase inhibitor. The drug improved overall survival in patients with FLT3 mutation-positive relapsed/refractory AML in clinical trials.

Full Story: